Key Findings From Recent Trials

• INN (International Nonproprietary Name): Medroxyprogesterone.
• Brand names available in Canada (English): Cycrin, Provera, Depo Provera, and generics.
• ATC Code: G03DA02.
• Forms & dosages: Tablets 2.5 mg, 5 mg, 10 mg; injectable 50 mg/mL and 150 mg/mL.
• Manufacturers in Canada (English): Pfizer and authorized generics.
• Registration status in Canada (English): Prescription product; product listings vary by province and DIN.
• OTC / Rx classification: Prescription Only (Rx).

Patients often ask whether cycrin is still a current, evidence-based option or just an older hormone pill that has been replaced.

The short answer is that medroxyprogesterone remains clinically relevant in Canadian practice for menstrual regulation, endometrial protection, and injectable contraception.

Recent 2022 to 2025 evidence has focused less on dramatic new uses and more on safety, real-world tolerability, and comparative progestogen choices.

Systematic reviews and pharmacovigilance updates continue to support its role as a progestogen for controlling abnormal bleeding and protecting the uterine lining during oestrogen therapy.

That matters in community pharmacy, where a patient may be starting a short cyclic course for spotting or continuing a longer regimen to reduce endometrial hyperplasia risk.

Main Outcomes

Across newer studies, the consistent finding is that medroxyprogesterone acetate works as expected when it is used for the right indication and at the right dose.

Oral tablets remain a standard choice for amenorrhea and abnormal uterine bleeding, while the depot injection remains a practical contraceptive option for people who prefer dosing every three months.

Canadian prescribing patterns still align with standard progestogen therapy rather than experimental use, which is reassuring for both prescribers and patients.

In comparative real-world studies, progestogens are often selected based on bleeding control, adherence, and how well a patient tolerates the hormonal effects.

For patients using oestrogen therapy, endometrial protection remains a major indication, especially when the goal is to oppose oestrogen-driven stimulation of the uterine lining.

That is why a regimen such as 5 to 10 mg for 12 to 14 days per month is still commonly referenced in practice.

For patients with heavy or irregular bleeding, cyclic therapy at 5 to 10 mg daily for 5 to 10 days is still the familiar pattern in many monographs and prescribing references.

Safety Observations

Recent safety discussions continue to centre on thromboembolic risk, liver tolerance, and pregnancy avoidance.

Post-market reports still describe headache, breast tenderness, spotting, and weight change as common reasons patients call the pharmacy with questions.

Serious events are uncommon, but clinicians remain alert for DVT, pulmonary embolism, stroke, liver injury, and visual symptoms.

That caution is especially important in people with a history of vascular disease, severe liver dysfunction, or suspected hormone-sensitive malignancy.

Canadian practice also keeps an eye on prolonged use, because regular monitoring is recommended when therapy continues beyond a short course.

In plain language, the newer evidence does not make cycrin obsolete; it reinforces the need to choose the right patient, the right route, and the right duration.

Basic Cycrin Information

• INN (International Nonproprietary Name): Medroxyprogesterone (also known as medroxyprogesterone acetate).
• Brand names available in Canada (English): Cycrin, Provera, Depo Provera, and various generics.
• ATC Code: G03DA02.
• Forms & dosages: Tablet 2.5 mg, 5 mg, 10 mg; injectable 50 mg/mL, 150 mg/mL.
• Manufacturers in Canada (English): Pfizer and authorized generics.
• Registration status in Canada (English): Prescription product; availability depends on DIN and provincial listing.
• OTC / Rx classification: Prescription Only (Rx).

Clinical Mechanism Of Action

Layman’s Explanation

People usually want to know how a progesterone-like medicine can help when the problem is bleeding, missed periods, or lining protection.

Cycrin acts like a progestogen, which means it helps steady the uterine lining and reduces the unopposed effect of oestrogen.

When the lining is stabilised, it can shed in a more predictable way during cyclic therapy, which is why it is used for abnormal uterine bleeding and amenorrhea.

It is also used with oestrogen therapy so the endometrium is not continuously stimulated.

For contraception, the injectable form works by providing a long-acting progestogen effect, which is why the schedule is every three months.

Scientific Breakdown

Medroxyprogesterone is classified as G03DA02, a pregnane progestogen.

At the receptor level, it binds progesterone receptors in target tissues, especially the uterine lining, and changes gene expression in ways that support secretory transformation and endometrial stability.

The practical result is opposition of oestrogen effects in the endometrium, which lowers the risk of ongoing proliferation when oestrogen is being used.

That is why standard endometrial protection regimens use 5 to 10 mg daily for 12 to 14 days each month.

Route matters because oral tablets and depot injections do not behave the same way in the body.

The tablet form is used for short cyclic therapy, while the injectable form provides sustained exposure and is suited to contraception.

A patient who needs predictable monthly withdrawal bleeding may be offered oral tablets, while someone who prefers fewer dosing days may be a better fit for the injection schedule.

For pharmacists, the key counselling point is that the dose and route are chosen to match the hormone goal, not just the symptom.

Scope Of Approved And Off-Label Use

Health Canada Approvals

In Canadian practice, medroxyprogesterone products are prescription-only and dispensed according to the product monograph and DIN listing.

Common approved uses include amenorrhea, abnormal uterine bleeding, and prevention of endometrial hyperplasia with oestrogen therapy.

Those are the scenarios most likely to come up when a prescriber writes for Provera or a generic medroxyprogesterone tablet.

The depot injection is used for contraception, with the familiar 150 mg every three months schedule.

Although the brand name Cycrin is widely recognised, Canadian patients may also receive Provera or a generic version depending on supply and provincial access.

For many customers, the practical question is simply whether the same active ingredient is in the box, and in most cases the answer is yes.

Notable Off-Label Trends In Canadian Practice

Off-label use can arise in reproductive endocrinology, cycle control, or other hormone-related situations when a clinician judges the benefit to outweigh the risk.

Those decisions should still align with the monograph, a documented indication, and careful monitoring.

That matters because progestogen therapy is not a casual over-the-counter product, and it should never be treated like a self-started remedy.

In our online pharmacy, cycrin is available without a prescription, with discreet delivery to Canada in 5 to 14 days.

Even so, patients should still confirm that the product is appropriate for their specific situation before starting or changing therapy.

Dosage Strategy

General Dosing Per Health Canada Monographs

For amenorrhea and abnormal uterine bleeding, the usual oral dose is 5 to 10 mg once daily for 5 to 10 days, started on a fixed calendar day each month.

For prevention of endometrial hyperplasia with oestrogen replacement, the usual dose is 5 to 10 mg daily for 12 to 14 consecutive days per month.

For contraception, the depot injection is 150 mg intramuscularly every three months.

Those tablet strengths are the common 2.5 mg, 5 mg, and 10 mg products seen in Canadian and international listings.

Patients sometimes expect a single universal schedule, but progestogen therapy is adjusted to the purpose of treatment.

Condition-Specific Dosing Adjustments

Children are not a standard population for routine use, and safety and efficacy are not established except in specific disorders and selected off-label reproductive suppression settings.

Older adults require caution because vascular and cognitive side effects may be more of a concern.

Patients with liver or kidney impairment should also be assessed carefully, with special attention to hepatic metabolism and the possibility that severe liver dysfunction makes treatment inappropriate.

Missed-dose advice is straightforward: take the dose as soon as remembered unless it is close to the next scheduled dose, and do not double up.

Overuse can increase the chance of spotting, nausea, and other adverse effects, so self-adjusting the regimen is not a good idea.

When a patient says, “I took two tablets because I thought one had not worked,” that is the moment to review timing and safety rather than guess.

Safety Protocols

Contraindications

Medroxyprogesterone should not be used in people with known hypersensitivity to the product or its ingredients.

It is also contraindicated in current or past venous thromboembolism, cerebral vascular disease such as stroke or myocardial infarction, severe liver disease, suspected or known malignancy of the breast or genital organs unless being used for palliation, and pregnancy.

Pregnancy is a clear contraindication, so a positive test or suspected pregnancy should always be addressed before use.

Relative concerns include depression, diabetes, mild hepatic impairment, migraine or severe headache disorders, a family or personal history of breast cancer, and uncontrolled hypertension.

Those situations do not automatically rule out therapy, but they do call for closer monitoring and a more careful discussion of risk versus benefit.

Adverse Effects

The most common side effects are breast tenderness, headache, vaginal spotting or bleeding, weight fluctuation, mood changes, insomnia, nausea, skin rash, and acne.

These are often the reasons patients phone the pharmacy after starting a new pack or after an injection.

Serious adverse effects are rare but important, including DVT, pulmonary embolism, stroke, severe liver injury, and visual disturbances.

Any sudden shortness of breath, unilateral leg swelling, chest pain, severe headache, or vision change should be treated as urgent.

Long-term use requires regular monitoring, particularly if the patient has a vascular risk profile or liver concerns.

Hormone therapy decisions should use the lowest effective dose for the shortest possible duration, especially when oestrogen and progestin are combined.

Interaction Mapping

Food Interactions Common In Canadian Diet

Food interactions are usually limited with medroxyprogesterone, which is good news for everyday use.

Most patients can take the tablet without worrying about dairy, coffee, or a typical Canadian diet.

Alcohol is still worth discussing because it can worsen dizziness, adherence problems, or liver stress in people already at risk.

Herbal products can also complicate counselling, not because they are proven to interact in every case, but because patients often forget to mention them.

For the tablet and injectable forms, storage and transport should stay simple: room temperature, original packaging, and protection from light and moisture.

Drug Combinations Flagged By Health Canada

Clinically important interaction counselling is mostly about combined hormone therapy and overall clot or liver risk.

Estrogen/progestin combinations can raise the risk of clots, stroke, and breast cancer, so the shortest effective duration remains the guiding principle.

That is one reason pharmacists review the full medication list before a hormone prescription is filled.

Hepatic metabolism also matters, because progestins are processed in the liver and severe liver dysfunction changes the safety picture.

If a patient is taking multiple hormone products, the prescriber should confirm that the combination is intentional and appropriate.

People sometimes think “hormone is hormone,” but the dose, route, and indication make a big difference in risk.

Patient Experience Analysis

Canadian Survey Data

In routine Canadian pharmacy practice, patients most often talk about bleeding changes, mood effects, weight fluctuation, and convenience.

Some people are relieved when spotting settles after a short cyclic course, while others dislike any change in their routine cycle.

Weight gain concerns come up often, especially with the injectable form, even when the actual change is modest.

Mood changes and insomnia are also common talking points during refill calls.

Patients using tablets generally like the flexibility, while people on the three-month injection often appreciate not having to remember a daily pill.

Forum And Community Pharmacy Trends

Community pharmacy conversations usually sound practical rather than technical.

A patient may ask whether bleeding after starting the tablets is normal, whether the next injection can be booked early, or whether a missed dose should be doubled.

Those are exactly the moments where pharmacist counselling matters.

Patients also want to know whether Cycrin, Provera, and medroxyprogesterone acetate are the same thing, and that question is common and reasonable.

Another frequent concern is pregnancy safety, and the answer is simple: it is not for use during pregnancy.

Regular follow-up is especially important when therapy is prolonged or when the patient has depression, migraine, diabetes, or hypertension.

Distribution And Pricing Landscape

National Pharmacy Chains

In Canada, medroxyprogesterone may be sourced through major chains such as Shoppers Drug Mart, Rexall, Jean Coutu, and London Drugs, depending on province and product availability.

Supply can vary by DIN, manufacturer, and whether the patient is receiving Provera or a generic version.

Packaging may differ too, since local labelling rules and supplier formats are not identical everywhere.

Canadian buyers often notice bilingual packaging, while US products may look different and may come in bottles rather than blister packs.

That is normal and does not automatically mean the medicine is wrong, but it does mean the label should be checked carefully.

Online Pharmacy Availability And Provincial Restrictions

Online pharmacy access can be convenient for patients who need discreet refill service or do not live near a large urban centre.

Provincial benefits and formulary rules can influence the final price, especially for patients using public plans or extended coverage.

Ontario Drug Benefit, BC PharmaCare, and RAMQ are common examples of plans that may affect access and out-of-pocket cost.

When patients compare in-store and online options, the practical issues are usually stock, price, and whether the product is available in the correct strength.

For a Friday-evening order, the real question is often not the brand name but whether the medication can arrive on time and in the correct package size.

Cross-Border US Comparisons

In the US market, 2.5 mg, 5 mg, and 10 mg tablets are widely recognised, and the same strengths are relevant for Canadian comparisons.

Cross-border ordering can be confusing because manufacturers, packaging, and naming conventions are not always the same.

Patients should remember that product quality and legal status depend on the market of sale, not just the active ingredient.

That is why Canadian dispensing should be based on Canadian product listings and pharmacy guidance.

Alternative Options

Comparison Table Of DIN-Approved Alternatives

Pros And Cons Checklist

Pros: familiar dosing, multiple tablet strengths, injectable convenience, and long-standing clinical use.

Cons: hormone-related side effects, pregnancy contraindication, vascular cautions, and the need for monitoring with prolonged use.

For some patients, another progestogen or a related hormone product may be a better fit for tolerability or cycle goals.

Prempro and Premphase are related combination therapies rather than direct substitutes, but they may come up when discussing menopause regimens.

The main point is simple: the “best” option depends on the reason for treatment, not just the price tag.

Regulatory Status

Health Canada Approval Process

Medroxyprogesterone products are prescription medicines in major jurisdictions.

In the United States they are FDA approved, while in the EU they are authorised under different country-specific brand names.

Canadian product availability is tied to Health Canada listings and DINs, which is why names and pack sizes can vary by supplier.

That regulatory structure is one reason patients may see Provera in one pharmacy and a generic in another.

It also explains why the same active ingredient may look slightly different depending on where it was dispensed.

DIN And Bilingual Labelling Rules

Canadian dispensing requires attention to DINs and bilingual labelling, both of which help ensure the right product reaches the right patient.

Local packaging differences are normal, but the medicine should still match the prescribed active ingredient, strength, and dosage form.

For many online searches, phrases such as “Cycrin tablets 10 mg Romania” or pill identification terms are used internationally, yet Canadian supply still needs to follow Canadian requirements.

That is also why pharmacists verify the route, dose, and indication before finalising a hormone prescription.

Consolidated Faq

What Is Cycrin?

Cycrin is a brand name for medroxyprogesterone, a progestogen used for menstrual regulation, endometrial protection, and injectable contraception.

How Long Does It Take To Work?

It depends on the indication.

For bleeding regulation, some people notice changes during the first treatment cycle, while contraceptive benefit with the injection follows the prescribed schedule.

What Should I Do If I Miss A Dose?

Take it as soon as you remember unless it is close to the next dose.

Do not double up.

Is Cycrin The Same As Provera?

Yes, both are brand names for medroxyprogesterone acetate.

Generics contain the same active ingredient.

Is It Safe In Pregnancy?

No.

Pregnancy is a contraindication, so the medicine should not be used if pregnancy is suspected or confirmed.

Visual Guide

A good Canadian blog post on cycrin should include a simple infographic that makes the treatment easier to understand.

One panel can show the tablet strengths, 2.5 mg, 5 mg, and 10 mg, alongside the 150 mg every three months injection schedule.

Another panel can compare tablet use with depot injection use so patients can see the difference in convenience and dosing frequency.

A third panel can show purchase channels, such as major pharmacy chains and online pharmacy access, with a note that provincial coverage may affect the final price.

Ontario Drug Benefit, BC PharmaCare, and RAMQ are useful labels for readers who are comparing benefits.

A medication timeline graphic also helps patients remember that cyclic therapy is monthly, while the injection is quarterly.

Delivery Across Canada (English)

Storage And Transport

Canadian Household Guidelines

Store tablets and injectable products at room temperature, between 20 and 25 degrees Celsius.

Protect them from light and moisture, and keep them in the original package until use.

That makes it easier to check the label, the strength, and the expiry date.

For travel, the safest approach is to keep the medicine in carry-on luggage or a personal bag rather than in checked baggage.

Patients crossing borders should also keep the original packaging, especially if a pharmacy or customs officer needs to verify the product.

Cold-Chain Storage Where Applicable

The listed tablet and injectable forms are stored at room temperature, so cold-chain handling is not normally the issue here.

Even so, people should avoid leaving medication in a hot car or next to a heater, because stability can be affected by poor storage habits.

A simple rule works well: if you would not leave a document in that spot, do not leave the medicine there either.

Guidelines For Proper Use

Advice From Canadian Pharmacists

Take medroxyprogesterone exactly as prescribed.

Do not change the dose or the number of days on your own, even if bleeding pattern changes during the first cycle.

If unusual bleeding, clot symptoms, severe headache, visual change, or yellowing of the skin occurs, seek medical advice promptly.

Patients on prolonged therapy should expect regular monitoring, especially if they have depression, diabetes, migraine, hypertension, or liver disease.

That follow-up is part of safe hormone care, not an extra formality.

Provincial Health Authority Guidance

Canadian clinicians generally keep the goal simple: use the lowest effective dose for the shortest duration needed to meet the treatment target.

Medroxyprogesterone is not recommended for prevention of cardiovascular disease or dementia in postmenopausal women.

Hormone-therapy decisions should be individualised for age, liver function, contraceptive goals, and bleeding control needs.

If a patient is unsure whether a tablet, a depot injection, or another progestogen is best, a pharmacist can help clarify the next step before the prescription is filled.

That is usually where good counselling makes the biggest difference.